Melanoma vaccine reduces death or cancer recurrence by 42%

Дата публикации: 23-10-2026 22:00:02

In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient's own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Moderna's cancer vaccine cuts melanoma recurrence risk in early trial: What we know	0	7.73	26-08-2026
2	Una vacuna personalizada experimental reduce el riesgo de recaída del melanoma	0	8.52	24-10-2026
3	Una vacuna personalizada contra el melanoma reduce un 42% el riesgo de recaída o muerte en un ensayo clínico	0	5.9	23-10-2026
4	Una vacuna personalizada contra el melanoma reduce un 42% el riesgo de recaída o muerte en un ensayo clínico	0	5.9	23-10-2026
5	mRNA vaccine reduced melanoma recurrence risk 42% after surgery	0	12.14	23-10-2026
6	A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning	0	9.7	22-10-2026
7	A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning	0	7.74	23-10-2026
8	mRNA 癌症疫苗将死亡复发风险减少 42%	0	20.18	23-10-2026
9	A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning	0	7.74	23-10-2026
10	Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy	0	7.13	24-10-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.93. Источник: medicalxpress.com.